TYDOCK PHARMA
TYDOCK PHARMA Srl is a knowledge-based biotechnology SME set up in 2006. In 2009, it received an award for being one of the most promising and innovative biotechnology companies in Italy from The Italian Institute for Foreign Trade (I.C.E.). The company is based on integrated drug discovery know-how which relies on 20 years of experience. It is a leading player in the drug discovery field and has seen many collaborations with universities and other biotechnology companies. The Company, as Rese... arch and Technology Transfer Centre, is also the recipient of research grants from the European Commission (FP7). TYDOCK PHARMA mainly operates in two business areas: DRUG DISCOVERY PRODUCTS TYDOCK PHARMA focuses on the discovery and early development of chemotherapeutic drugs, with particular emphasis on parasitic diseases (tuberculosis, malaria and protozoarian infections). INNOVATION PROJECT DEVELOPMENT TYDOCK PHARMA is involved in various technology transfer projects aimed at translating innovative technologies from basic research to industrial application.
TYDOCK PHARMA
Industry:
Biopharma Biotechnology
Founded:
2006-01-01
Address:
Modena, Emilia-Romagna, Italy
Country:
Italy
Website Url:
http://www.tydockpharma.com
Total Employee:
1+
Status:
Closed
Email Addresses:
[email protected]
Total Funding:
71.43 K EUR
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta SPF Apple Mobile Web Clips Icon Google Font API Google Analytics Google Universal Analytics Apache Google Apps For Business YouTube
Current Employees Featured
Founder
Investors List
EASME - EU Executive Agency for SMEs
EASME - EU Executive Agency for SMEs investment in Grant - TYDOCK PHARMA
Official Site Inspections
http://www.tydockpharma.com
- Host name: 45.144.60.8
- IP address: 45.144.60.8
- Location: Italy
- Latitude: 43.1479
- Longitude: 12.1097
- Timezone: Europe/Rome
More informations about "TYDOCK PHARMA"
www.tydockpharma.com
Animal by-products manufacturing Waste product management. PILOT-ABP. pilot-abp.eu. 7FP Collaborative ProjectSee details»
The Company - Company Profile - tydockpharma.com
1st January 2020. TYDOCK PHARMA Srl is a knowledge-based biotechnology SME. In 2009, it received an award for being one of the most promising and innovative biotechnology …See details»
TYDOCK PHARMA - Crunchbase Company Profile & Funding
Contact Email [email protected] TYDOCK PHARMA Srl is a knowledge-based biotechnology SME set up in 2006. In 2009, it received an award for being one of the most …See details»
Management - Company Profile - tydockpharma.com
1st January 2023. Dr. Massimiliano Pizzi - CEO. Luisa Pecorari (LP) - Ph.D. Marketing and molecular biology. Co-founder and Owner of TYDOCK PHARMA srl. LP has a degree in …See details»
TYDOCK PHARMA | LinkedIn
TYDOCK PHARMA | 201 follower su LinkedIn. Technology transfer projects aimed at translating innovative technologies from basic research to industrial applications | TYDOCK PHARMA Srl …See details»
TYDOCK PHARMA SRL Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for TYDOCK PHARMA SRL of MODENA, MODENA. Get the latest business insights from Dun & Bradstreet.See details»
Tydock s.r.l. - VentureRadar
Website: http://www.tydockpharma.com. Develops chemotherapeutic drugs for parasitic diseases and facilitates technology transfer projects for innovative technologies ...See details»
TYDOCK PHARMA Corporate Headquarters, Office Locations and …
TYDOCK PHARMA is headquartered in Modena, Str. Gherbella, 294, Italy, and has 1 office location.See details»
Company Information - RocketReach
TYDOCK PHARMA Srl is a knowledge-based biotechnology SME set up in 2006. In 2009, it received an award for being one of the most promising and innovative biotechnology …See details»
TYDOCK PHARMA - Products, Competitors, Financials, Employees ...
Tydockpharma.com. Overview & Products; Founded Year 2006. About TYDOCK PHARMA. Tydock Pharma is a biotechnology company engaged in drug discovery and development …See details»
TYDOCK PHARMA - Craft
TYDOCK PHARMA is a drug discovery and biotech company. It discovers and develops chemotherapeutic drugs, with particular emphasis on parasitic diseases (tuberculosis, malaria, …See details»
TYDOCK PHARMA - Overview, News & Similar companies
Who is TYDOCK PHARMA. TYDOCK PHARMA S.r.l. is a chemistry-driven research-intensive biostart-up company born in 2006 which was selected among the 15 Most Established Ita lian …See details»
www.tydockpharma.com
Lasciare questo campo vuoto. TYDOCK PHARMA S.r.l. E-mail. E-mail *See details»
Company Profile - tydockpharma.com
Drug Discovery and biotech. E-mail © Tydockpharma .Tydockpharma . Vat number 03078190364 .See details»
TYDOCK PHARMA - Company Profile - Tracxn
TYDOCK PHARMA - Developer of chemotherapeutic drugs for parasitic diseases. Raised funding over 3 rounds from 2 investors. Founded by Alberto Venturelli, Costi Maria Paola and 2 others …See details»
Tydock Pharma Srl - Drug pipelines, Patents, Clinical trials - Synapse
Explore Tydock Pharma Srl with its drug pipeline, therapeutic area, technology platform, 9 literature, Drug:Ty-38c.See details»
Startup Showcase: TYDOCK PHARMA – Pioneering Drug Discovery …
Mar 3, 2023 TYDOCK PHARMA is a biotechnology SME based in Modena, Emilia-Romagna, Italy, with a primary focus on the discovery and early development of chemotherapeutic drugs …See details»
☑️Tydock Pharma — Consulting Organization from
Tydock Pharma — Consulting Organization from Italy, has experience with Horizon 2020 (2014 - 2020), it`s involved in Agriculture, Health, Science & Innovation sectorsSee details»
Detection of drug resistant bacteria - Drug Resistant Bacteria
Antibiotic resistance is a growing problem in hospitals, and the phenomenon is already responsible for increased disease burden globally. Both the importance and urgency of this …See details»
More Medicine For Tuberculosis "MM4TB" - tydockpharma.com
More than 130 years after Koch’s discovery of Mycobacterium tuberculosis as its etiological agent, tuberculosis (TB) still affects humankind and was responsible for 1.3 million deaths in 2012. …See details»